Nanotechnological Advances in the Treatment of Epilepsy

Author(s):  
Ola Asem Mahmoud Abdou Ali ◽  
Mohd. Farooq Shaikh ◽  
M Saquib Hasnain ◽  
Farheen Sami ◽  
Abdullah Khan ◽  
...  

: Epilepsy is known as one of the major challenges for medical science. The sudden appearance of a seizure has been a significant health emergency as it may lead to further complications. Although key advancement have been achieved in terms of pharmacological approaches for epilepsy, many issues remain uncertain. Lipid carriers have been at the forefront, especially in neurodegenerative diseases such as epilepsy, Alzheimer’s, dementia, etc. The blood-brain barrier still appears to be a major impediment in the successful treatment of epileptic seizures. This is mainly due to the limited bioavailability of most anti-convulsant drugs. The present review encompasses the issues underlying the current approach for epilepsy drug treatment and highlights the newer, novel, and more precise drug delivery system to manage seizures. The advantage of using a lipid-based delivery system is its superior absorption in the brain cells. Ample evidence shows that reducing the particle size also infuses the drug easily through the blood-brain barrier. The application of liposomes, polymeric nanoparticles, metallic nanoparticles, and solid lipid nanoparticles for the treatment and management of epilepsy has been highlighted in the present review. This review will provide an overview of the current status of the treatment and recent advances in the treatment of epilepsy.

Author(s):  
Falaq Naz ◽  
Yasir Hasan Siddique

: Neurodegenerative diseases including Alzheimer’s, Parkinson’s and Huntington disease are have serious concern due to its effect on the quality of life of affected persons. Neurodegenerative diseases have some limitations for both diagnostic as well as at treatment level. Introducing nanotechnology, for the treatment of these diseases may contribute significantly in solving the problem. There are several treatment strategies for the neurodegenerative diseases, but their limitations are the entry into the due to the presence of the blood-brain barrier (BBB). The present review highlights the application of nanotechnology during last 20 years for the treatment of neurodegenerative diseases.


Viruses ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1294
Author(s):  
Yogesh R. Suryawanshi ◽  
Autumn J. Schulze

Glioblastoma is one of the most difficult tumor types to treat with conventional therapy options like tumor debulking and chemo- and radiotherapy. Immunotherapeutic agents like oncolytic viruses, immune checkpoint inhibitors, and chimeric antigen receptor T cells have revolutionized cancer therapy, but their success in glioblastoma remains limited and further optimization of immunotherapies is needed. Several oncolytic viruses have demonstrated the ability to infect tumors and trigger anti-tumor immune responses in malignant glioma patients. Leading the pack, oncolytic herpesvirus, first in its class, awaits an approval for treating malignant glioma from MHLW, the federal authority of Japan. Nevertheless, some major hurdles like the blood–brain barrier, the immunosuppressive tumor microenvironment, and tumor heterogeneity can engender suboptimal efficacy in malignant glioma. In this review, we discuss the current status of malignant glioma therapies with a focus on oncolytic viruses in clinical trials. Furthermore, we discuss the obstacles faced by oncolytic viruses in malignant glioma patients and strategies that are being used to overcome these limitations to (1) optimize delivery of oncolytic viruses beyond the blood–brain barrier; (2) trigger inflammatory immune responses in and around tumors; and (3) use multimodal therapies in combination to tackle tumor heterogeneity, with an end goal of optimizing the therapeutic outcome of oncolytic virotherapy.


1984 ◽  
Vol 436 (1 Multiple Scle) ◽  
pp. 52-67 ◽  
Author(s):  
WALLACE W. TOURTELLOTTE ◽  
MICHAEL J. WALSH ◽  
ROBERT W. BAUMHEFNER ◽  
SUSAN M. STAUGAITIS ◽  
PAUL SHAPSHAK

Biomaterials ◽  
2015 ◽  
Vol 37 ◽  
pp. 345-352 ◽  
Author(s):  
Hui Yao ◽  
Kaiyuan Wang ◽  
Yi Wang ◽  
Shanshan Wang ◽  
Jianfeng Li ◽  
...  

2019 ◽  
Vol 7 (01) ◽  
pp. 05-06
Author(s):  
Navin Banarase

Nasya is one of the most important Panchakarma procedures done in Ayurveda. It is mostly done for the Urdhvajatrugata Vikara. The drug has effects on the Central Nervous System also. Hence it is important to elaborate on the concept of Sharir according to Ayurveda and Modern Medical Science to understand this drug delivery route. Nasya gives the drug mainly gets absorbed by capillaries in the nasal mucosa and also crosses the blood-brain barrier (BBB) as mostly the drug is prepared in the form of Sneha. This article will explain the Sharir concept related to the Nasya procedure.


2021 ◽  
Vol 17 (10) ◽  
pp. 2034-2042
Author(s):  
Wenjing Ma ◽  
Huan Peng ◽  
Kewei Liu ◽  
Yaguo Wang ◽  
Wei Wang ◽  
...  

Tuberculous meningitis (TBM) is an incurable disease with high mortality. It is an extrapulmonary tuberculosis caused by mycobacterium tuberculosis which penetrated the blood-brain barrier and infected the meninges. Mycobacterium tuberculosis lurking in the body mainly reside in macrophages. Anti-tuberculous drugs usually can not target the blood-brain barrier and macrophages, the drug concentration in the lesion is low, which cannot effectively kill mycobacterium tuberculosis, making TBM difficult to treat. Targeted drug delivery systems can target drugs to specific nidus. In the study, we constructed a drug delivery system, which was a cell penetrate peptide B6 and phosphatidylserine (PS) modified polyethylene glycol (PEG) nanomaterial to target the blood-brain barrier and to target macrophages. This nanomaterial was a combined anti-tuberculosis drug delivery system encapsulating antituberculosis drugs rifampicin and pyrazinamide, designed to target macrophages in the brain and kill mycobacterium tuberculosis lurking in the macrophages. We have physically characterized the drug delivery system, and verified the bactericidal ability at cellular and animal level. Results have shown that the targeted drug delivery system had a remarkable efficacy to treat TBM in mice.


Sign in / Sign up

Export Citation Format

Share Document